These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 37960806)
21. Prognostic value analysis of urokinase-type plasminogen activator receptor in oral squamous cell carcinoma: an immunohistochemical study. Bacchiocchi R; Rubini C; Pierpaoli E; Borghetti G; Procacci P; Nocini PF; Santarelli A; Rocchetti R; Ciavarella D; Lo Muzio L; Fazioli F BMC Cancer; 2008 Aug; 8():220. PubMed ID: 18673553 [TBL] [Abstract][Full Text] [Related]
22. [Expression of RACK1 and EGP40 in oral squamous cell carcinoma and its correlation with clinicopathological features and prognosis]. Duan YH; Wu KL; Mei J; Zhou YY; Liu MS Shanghai Kou Qiang Yi Xue; 2023 Aug; 32(4):385-390. PubMed ID: 38044732 [TBL] [Abstract][Full Text] [Related]
23. Salivary KLK5 and uPA are potential biomarkers for malignant transformation of OLK and OLP. Kang Y; Chen J; Li X; Luo M; Chen H; Cui B; Wang L; Lv D; Feng Y; Zhang P Cancer Biomark; 2021; 31(4):317-328. PubMed ID: 33896830 [TBL] [Abstract][Full Text] [Related]
25. Prognostic relevance of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in gastric cancer. Ito H; Yonemura Y; Fujita H; Tsuchihara K; Kawamura T; Nojima N; Fujimura T; Nose H; Endo Y; Sasaki T Virchows Arch; 1996 Feb; 427(5):487-96. PubMed ID: 8624578 [TBL] [Abstract][Full Text] [Related]
26. High expression of the urokinase plasminogen activator and its cognate receptor associates with advanced stages and reduced disease-free interval in papillary thyroid carcinoma. Ulisse S; Baldini E; Sorrenti S; Barollo S; Gnessi L; Catania A; Pellizzo MR; Nardi F; Mian C; De Antoni E; D'Armiento M; Frati L J Clin Endocrinol Metab; 2011 Feb; 96(2):504-8. PubMed ID: 21106716 [TBL] [Abstract][Full Text] [Related]
27. Urokinase plasminogen activator receptor (uPAR) and plasminogen activator inhibitor-1 (PAI-1) are potential predictive biomarkers in early stage oral squamous cell carcinomas (OSCC). Magnussen S; Rikardsen OG; Hadler-Olsen E; Uhlin-Hansen L; Steigen SE; Svineng G PLoS One; 2014; 9(7):e101895. PubMed ID: 24999729 [TBL] [Abstract][Full Text] [Related]
28. High level of urokinase-type plasminogen activator is a new prognostic marker in patients with gastric carcinoma. Cho JY; Chung HC; Noh SH; Roh JK; Min JS; Kim BS Cancer; 1997 Mar; 79(5):878-83. PubMed ID: 9041148 [TBL] [Abstract][Full Text] [Related]
29. Lactic acid-induced M2-like macrophages facilitate tumor cell migration and invasion via the GPNMB/CD44 axis in oral squamous cell carcinoma. Lin Y; Qi Y; Jiang M; Huang W; Li B Int Immunopharmacol; 2023 Nov; 124(Pt B):110972. PubMed ID: 37806107 [TBL] [Abstract][Full Text] [Related]
30. GPNMB-Positive Cells in Head and Neck Squamous Cell Carcinoma-Their Roles in Cancer Stemness, Therapy Resistance, and Metastasis. Kawasaki Y; Suzuki H; Suzuki S; Yamada T; Suzuki M; Ito A; Hatakeyama H; Miura M; Omori Y Pathol Oncol Res; 2022; 28():1610450. PubMed ID: 36061142 [No Abstract] [Full Text] [Related]
31. Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis. Ohba K; Miyata Y; Kanda S; Koga S; Hayashi T; Kanetake H J Urol; 2005 Aug; 174(2):461-5. PubMed ID: 16006865 [TBL] [Abstract][Full Text] [Related]
32. The urokinase plasminogen activation system in gastroesophageal cancer: A systematic review and meta-analysis. Brungs D; Chen J; Aghmesheh M; Vine KL; Becker TM; Carolan MG; Ranson M Oncotarget; 2017 Apr; 8(14):23099-23109. PubMed ID: 28416743 [TBL] [Abstract][Full Text] [Related]
33. Urokinase plasminogen activator and its inhibitor type-1 as prognostic factors in differentiated thyroid carcinoma patients. Horvatic Herceg G; Herceg D; Kralik M; Kulic A; Bence-Zigman Z; Tomic-Brzac H; Bracic I; Kusacic-Kuna S; Prgomet D Otolaryngol Head Neck Surg; 2013 Oct; 149(4):533-40. PubMed ID: 23835563 [TBL] [Abstract][Full Text] [Related]
34. Role of urokinase plasminogen activator and its receptor in metastasis and invasion of neuroblastoma. Li P; Gao Y; Ji Z; Zhang X; Xu Q; Li G; Guo Z; Zheng B; Guo X J Pediatr Surg; 2004 Oct; 39(10):1512-9. PubMed ID: 15486896 [TBL] [Abstract][Full Text] [Related]
35. Urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 and type 2 in stage I malignant melanoma. Stabuc B; Markovic J; Bartenjev I; Vrhovec I; Medved U; Kocijancic B Oncol Rep; 2003; 10(3):635-9. PubMed ID: 12684636 [TBL] [Abstract][Full Text] [Related]
36. Urokinase-type plasminogen activator and plasminogen activator inhibitor-1 as a prognostic factor in human colorectal carcinomas. Fujii T; Obara T; Tanno S; Ura H; Kohgo Y Hepatogastroenterology; 1999; 46(28):2299-308. PubMed ID: 10521987 [TBL] [Abstract][Full Text] [Related]
37. Prognostic impact of urokinase-type plasminogen activator system components in clear cell renal cell carcinoma patients without distant metastasis. Fuessel S; Erdmann K; Taubert H; Lohse-Fischer A; Zastrow S; Meinhardt M; Bluemke K; Hofbauer L; Fornara P; Wullich B; Baretton G; Magdolen V; Wirth MP; Kotzsch M BMC Cancer; 2014 Dec; 14():974. PubMed ID: 25519168 [TBL] [Abstract][Full Text] [Related]